Welcome to our dedicated page for SANUWAVE Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SANUWAVE Health, Inc. filings document a Nevada medical-device company focused on directed-energy systems for advanced wound care and regenerative medicine. Form 8-K reports record results of operations, preliminary financial information, investor presentation materials and material-event disclosures related to the company’s wound care business.
Regulatory filings also cover governance and capital-market disclosure subjects, including annual meeting proxy proposals, director elections, auditor ratification, stockholder advisory votes on executive compensation, officer appointments, compensatory arrangements and separation agreements. Additional filings document accounting matters such as non-reliance on previously issued financial statements connected to historical sales and use tax liabilities.
Sanuwave Health, Inc. determined that several previously issued quarterly and annual financial statements can no longer be relied upon due to unrecorded state sales and use tax obligations. The company plans to restate its 2024 annual results and all affected 2024–2025 interim periods in its 2025 Form 10-K.
Based on its ongoing review, Sanuwave expects to record an aggregate increase in reported liabilities of between $4.9 million and $5.2 million as of December 31, 2025. It also expects additional expenses, including taxes, interest and penalties, of $1.6 million to $1.8 million for 2024 and $1.7 million to $1.9 million for 2025. Management is evaluating the impact on internal control over financial reporting and may identify additional material weaknesses, with conclusions to be disclosed in the 2025 Form 10-K, which it expects to file on time.
SANUWAVE Health executive receives stock option grant
SANUWAVE Health, Inc. granted Exec VP of Sales David Timothy Wern a stock option for 2,500 shares of common stock on January 30, 2026. The option has an exercise price of $26.96 per share and expires on January 30, 2036.
The filing shows the full 2,500 options are held directly after the transaction. According to the footnote, these options will vest over three years in 12 equal quarterly installments starting from the grant date, tying the award to ongoing service and performance over time.
SANUWAVE Health reported that Chief Executive Officer and director Morgan C. Frank received a new stock option grant. On 01/30/2026, he was awarded options to purchase 24,000 shares of common stock at an exercise price of $26.96 per share, expiring on 01/30/2031.
The options were granted at no cost on the grant date and will vest in four equal installments on the last day of each quarter during 2026, aligning vesting with the company’s quarterly performance periods.
Sanuwave Health, Inc. filed an amended report to update the outcome of its advisory vote on how often shareholders will be asked to approve executive compensation. After the 2025 annual meeting, where shareholders favored a one-year cycle, the Board decided on annual say-on-pay votes.
The Board resolved on January 7, 2026 to hold these advisory votes every year until the next required vote on frequency, which will occur no later than the company’s 2031 annual meeting of stockholders. No other items from the prior report were changed.
SANUWAVE Health Chief Executive Officer Morgan C. Frank, who also serves as a director, reported receiving a new stock option award. On 12/31/2025, he was granted a stock option to buy 1,540 shares of common stock at an exercise price of $29.84 per share. The filing states that these options were fully vested at the grant date, meaning they are immediately exercisable, and they carry an expiration date of 12/31/2030. After this grant, Frank beneficially owns 1,540 derivative securities in the form of these stock options, held directly.
SANUWAVE Health, Inc. director Tyler James reported receiving a stock option grant. On December 31, 2025, he was awarded 1,540 stock options giving the right to buy common stock at an exercise price of $29.84 per share. These options are shown as fully vested at the grant date and expire on December 31, 2030. After this grant, James beneficially owned 1,540 derivative securities, all held directly.
SANUWAVE Health, Inc. reported an insider equity award for director Jeffrey Blizard. On 12/31/2025, he received a stock option to purchase 1,540 shares of common stock at an exercise price of $29.84 per share, expiring on 12/31/2030.
The option was fully vested on the grant date, meaning it was immediately exercisable. Following this award, Blizard beneficially owns 1,540 derivative securities related to the company’s common stock, held as a direct ownership position.
SANUWAVE Health affiliated holders reported sales of the company’s common stock by a group including JEB Partners, L.P. and related investment entities. On December 11, 2025, they sold 13,500 shares at a weighted average price of $31.2798, followed by a sale of 6,500 shares on December 12, 2025 at a weighted average price of $21.0444, both reported with transaction code “S.”
Following these transactions, 63,999 shares of SANUWAVE Health common stock were reported as indirectly beneficially owned through JEB Partners, L.P., with indirect interests attributed to Manchester Management Company, LLC, Manchester Management PR, LLC and James E. Besser. Additional lines report 2,000 shares directly owned by James E. Besser, 863,980 shares owned directly by Manchester Explorer, L.P., and 52,653 securities and warrants directly owned by Morgan C. Frank, with each party disclaiming beneficial ownership beyond their pecuniary interest.
Sanuwave Health (SNWV) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025.
The company also scheduled a business update conference call for November 7, 2025 at 8:30 a.m. EST. The press release is included as Exhibit 99.1, with materials available on the investor relations website. The information under Item 2.02 is being furnished, not filed.
SANUWAVE Health (SNWV) reported Q3 2025 results with revenue of $11.5M (up 22% year over year) and gross margin of 78%. Operating income was $1.5M. Net income reached $10.3M, driven by a $6.1M favorable change in warrant fair value and $5.0M other income from a patent sale.
Year to date, revenue was $31.0M (up 39%) and operating income was $4.3M. Consumables and parts contributed $7.0M in the quarter; system revenue was $4.4M. Stock‑based compensation totaled $1.4M in Q3.
Balance sheet and liquidity: SANUWAVE closed a new credit agreement with a $23.0M secured term loan (maturing 2029) and a $5.0M revolver (undrawn availability $4.3M as of Sept 30, 2025), and repaid prior senior secured debt. Management states that refinancing and positive operating income alleviated prior going‑concern doubt. Cash was $9.6M; total liabilities were $38.5M. Shares outstanding were 8,576,164 as of Nov 3, 2025.